RNAGBP
Avidity Biosciences, Inc.
A biopharmaceutical company developing antibody oligonucleotide conjugates (AOCs) — antibodies that carry RNA-based therapies to specific cells, targeting rare muscle diseases. Founded in 2012 in La Jolla, California, the name plays on "avidity," the combined strength of antibody-antigen binding, fitting its mission of linking antibodies to oligonucleotides. Its lead programs aim at conditions like myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy.
CUSIP: 05370A108HealthcareUS1 holder